-+ 0.00%
-+ 0.00%
-+ 0.00%

VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 203 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VS-7375 ORAL KRAS G12D (ON/OFF) INHIBITOR FOR KRAS G12D-MUTATED METASTATIC COLORECTAL CANCER

路透·07/28/2026 20:01:00

登錄查看新聞詳情